Osteoporosis and Prostate Cancer
Author Information
Author(s): Dhillon T, Waxman J
Primary Institution: Imperial College of Science, Technology & Medicine
Hypothesis
The development of osteoporosis is a significant side effect of antiandrogen therapy in prostate cancer patients.
Conclusion
Osteoporosis is a major concern for prostate cancer patients undergoing antiandrogen treatment, but its effects can be mitigated with bisphosphonate therapy.
Supporting Evidence
- The cumulative risk of fracture at 7 years was 28% in castrated men and 1% in those treated with a GnRH agonist.
- 6% of men had an osteoporotic fracture during 6 or more months of anti-androgen therapy.
- 20% of men treated for 10 years had osteoporotic fractures.
- Bone mineral density decreased significantly after 6 months of treatment.
- Bisphosphonate treatment can prevent significant changes in bone mineralization.
Takeaway
Prostate cancer treatment can lead to weak bones, but giving certain medicines can help keep bones strong.
Methodology
The article reviews multiple studies on the effects of antiandrogen therapy on bone mineral density and the potential benefits of bisphosphonate treatment.
Limitations
The article does not provide specific details on the bisphosphonate dosage regimen needed for effective treatment.
Participant Demographics
The studies referenced include men with prostate cancer, with varying treatment regimens and follow-up periods.
Statistical Information
Confidence Interval
95% CI 2.71–4.43
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website